click below
click below
Normal Size Small Size show me how
NCC -Pharmacology 1
Chapters 1 & 2
Question | Answer |
---|---|
urticaria | Hives |
Medicines not bonded to proteins. Usually dissolved in blood and does not require a protein carrier. | unbound drug |
Brand name, or proprietary name, followed by the symbol ®. | Trademark |
A severe adverse effect. | Toxicity |
A person's need for a higher drug dosage to produce the same effects that a lower dosage once provided. | Tolerence |
teratogen (teratogenic) | Agent that produces birth defects. |
synergistic effect | The combined effect of two drugs is greater than the sum of the effect of each drug given alone. |
Symptoms of drug therapy for which the nurse has a responsibility to monitor the patient and report these symptoms to the health care provider. | serious adverse effects |
Classifications of controlled substances | Schedules |
Cellular protein that binds to a hormone so that a response can be elicited. | Receptors |
proprietary name | Drug name followed by the symbol ® indicating that the name is registered and that its use is restricted to the owner of the drug, who is usually the manufacturer. Also known as trademark or brand name. |
Collection of voluntary reports regarding adverse drug events of FDA-approved drugs. | postmarketing surveillance |
Physicians' Desk Reference (PDR) | A compendium compiled annually, containing information about drugs, primarily prescription drugs and products used in diagnostic procedures in the United States, supplied by their manufacturers. |
The study of drugs and their actions on living organisms. | pharmacology |
The study of the mathematical relationships among the absorption, distribution, metabolism, and excretion of individual medicines over time. | pharmacokinetics |
pharmacogenetics | Effect of a drug action that varies from a predicted drug response because of genetic factors or hereditary influence. |
The study of interactions between drugs and their receptors and the series of events that result in a pharmacologic response. | pharmacodynamics |
Drugs that attach and elicit a small response but also block other responses. | partial agonists |
Subcutaneous, intramuscular, or intravenous method of administration; treatment by injection. | parenteral (parenterally) |
over-the-counter (OTC) drugs | Drugs that are sold without a prescription in a pharmacy or the health section of department or grocery stores. |
onset of action | Time when the concentration of a drug at the site of action is sufficient to start a physiologic (pharmacologic) response. |
official name | The name under which a drug is listed by the U.S. Food and Drug Administration (FDA). |
nocebo effect | Latin, "I will harm." The effect that occurs when the patient's negative expectations about therapy result in less than optimal outcomes. |
Application submitted to the FDA formally requesting approval to market a new drug for human use. | New Drug Application |
Therapeutic drugs used to prevent or treat diseases. | medicines |
Section of the patient's chart listing all medications to be administered. | medication administration record (MAR) |
Martindale—The Complete Drug Reference | Comprehensive text for information on drugs in current use throughout the world; published by the Royal Pharmaceutical Society of Great Britain. |
interference | The drug interaction that occurs when the first drug inhibits the metabolism or excretion of the second drug, causing increased activity of the second drug. |
A drug interaction that occurs when the first drug is chemically incompatible with the second drug, causing deterioration when both drugs are mixed in the same syringe or solution. | incompatibility |
idiosyncratic reaction | An adverse drug reaction resulting from a genetic polymorphism. |
Raised, irregularly shaped patches on the skin that itch severely. | hives |
health orphans | Rare diseases that pharmaceutical manufacturers were reluctant to develop products for because they were unable to recover the costs of the research involved. |
half-life | The amount of time required to eliminate 50% of the drug from the body. |
generic name | Before a drug becomes official, it is given a generic name or common name that may be used in any country and by any manufacturer. |
Act passed in 1938 authorizing the FDA to determine the safety of drugs before marketing and to ensure that certain labeling specifications and standards in advertising are met. | Federal Food, Drug, and Cosmetic Act |
Elimination of drug metabolites and, in many cases, the active drug itself from the body. | excretion |
enteral | Administering a drug directly into the gastrointestinal tract by oral, rectal, or nasogastric routes. |
duration of action | The length of time a drug has a pharmacologic effect on an individual. |
drug tolerance | When a patient requires increases in dosing to achieve the same therapeutic effect. |
drug metabolism | The process by which the body inactivates medicines. |
Drug Interaction Facts | The most comprehensive book available on the subject of drug interactions; published by Facts and Comparisons. |
When the action of one drug is altered by the action of another. | drug interaction |
Drug Facts and Comparisons | Comprehensive compendium of drug information published by Facts and Comparisons. |
drug blood level | An assay to determine the amount of drug present in a blood sample. |
drug accumulation | The effect that occurs when the previously administered drug dose has not yet been metabolized or excreted when the next dose is administered. |
drugs | Chemical substances that have an effect on living organisms. |
distribution | The ways in which drugs are transported by the circulating body fluids to the sites of action (receptors), metabolism, and excretion. |
displacement | The displacement from protein-binding sites of the first drug by a second drug, increasing the activity of the first drug. |
desired action | The expected response that occurs when a drug enters a patient and is absorbed and distributed. |
Controlled Substances Act | Act passed in 1970 designed to improve the administration and regulation of manufacturing, distributing, and dispensing of controlled drugs. |
common adverse effects | Symptoms that can be alleviated or prevented by actions of the nurse or patient that will require immediate planning for patient education. |
chemical name | The chemical constitution of a drug, the exact placing of its atoms or molecular groupings; this terminology is significant to a chemist. |
carcinogenicity | The ability of a drug to induce living cells to mutate and become cancerous. |
brand name | Drug name followed by the symbol ® indicating that the name is registered and that its use is restricted to the owner of the drug, who is usually the manufacturer. |
biotransformation | The process by which the body inactivates drugs. Also called metabolism. |
antagonistic effect | A drug interaction in which one drug interferes with the action of another. |
antagonists | Drugs that attach to a receptor but do not stimulate a response; used to block the receptor from attaching to another substance. |
allergic reactions | Reaction to a drug in which a patient has developed antibodies to previous exposure of the drug, and upon re-exposure, the antibodies cause a reaction such as hives. |
agonists | Drugs that interact with a receptor to stimulate a response. |
adverse effects | The undesirable responses produced by a drug (other than its intended effect) when it affects more than one body system. Also known as side effects. |
ADME | Acronym for the 4 stages of the drug cycle: absorption, distribution, metabolism, and excretion. |
additive effect | A drug interaction that occurs when two drugs with similar actions are taken, thus doubling the effect. |
absorption | When a drug moves from its site of administration to the blood. |